CN103232446A - 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 - Google Patents
一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 Download PDFInfo
- Publication number
- CN103232446A CN103232446A CN2013101828062A CN201310182806A CN103232446A CN 103232446 A CN103232446 A CN 103232446A CN 2013101828062 A CN2013101828062 A CN 2013101828062A CN 201310182806 A CN201310182806 A CN 201310182806A CN 103232446 A CN103232446 A CN 103232446A
- Authority
- CN
- China
- Prior art keywords
- oxo
- thiophene
- chloro
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310182806.2A CN103232446B (zh) | 2013-05-17 | 2013-05-17 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
PCT/CN2014/077667 WO2014183666A1 (zh) | 2013-05-17 | 2014-05-16 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310182806.2A CN103232446B (zh) | 2013-05-17 | 2013-05-17 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103232446A true CN103232446A (zh) | 2013-08-07 |
CN103232446B CN103232446B (zh) | 2015-09-23 |
Family
ID=48880526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310182806.2A Active CN103232446B (zh) | 2013-05-17 | 2013-05-17 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103232446B (zh) |
WO (1) | WO2014183666A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103242307A (zh) * | 2013-05-17 | 2013-08-14 | 天津药物研究院 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
WO2014183666A1 (zh) * | 2013-05-17 | 2014-11-20 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
CN106478661A (zh) * | 2015-08-25 | 2017-03-08 | 华北制药集团新药研究开发有限责任公司 | 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026135A1 (de) * | 2003-09-15 | 2005-03-24 | Bayer Healthcare Ag | Verfahren zur herstellung von 4-(4-aminophenyl)-3-morpholinon |
CN1763018A (zh) * | 2005-09-30 | 2006-04-26 | 天津药物研究院 | 噁唑烷酮类化合物 |
CN101220002A (zh) * | 2007-12-28 | 2008-07-16 | 天津药物研究院 | 作为抗菌剂的噁唑烷酮类化合物 |
WO2011004392A1 (en) * | 2009-07-06 | 2011-01-13 | Glenmark Generics Limited | Crystalline form of prasugrel hydrobromide, preparation and application thereof |
CN102050819A (zh) * | 2009-11-10 | 2011-05-11 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
CN102464658A (zh) * | 2010-11-03 | 2012-05-23 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007028406A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
CN103626749A (zh) * | 2012-08-21 | 2014-03-12 | 苏州泽璟生物制药有限公司 | 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途 |
CN103242307B (zh) * | 2013-05-17 | 2015-08-12 | 天津药物研究院有限公司 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
CN103232446B (zh) * | 2013-05-17 | 2015-09-23 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
-
2013
- 2013-05-17 CN CN201310182806.2A patent/CN103232446B/zh active Active
-
2014
- 2014-05-16 WO PCT/CN2014/077667 patent/WO2014183666A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026135A1 (de) * | 2003-09-15 | 2005-03-24 | Bayer Healthcare Ag | Verfahren zur herstellung von 4-(4-aminophenyl)-3-morpholinon |
CN1763018A (zh) * | 2005-09-30 | 2006-04-26 | 天津药物研究院 | 噁唑烷酮类化合物 |
CN101220002A (zh) * | 2007-12-28 | 2008-07-16 | 天津药物研究院 | 作为抗菌剂的噁唑烷酮类化合物 |
WO2011004392A1 (en) * | 2009-07-06 | 2011-01-13 | Glenmark Generics Limited | Crystalline form of prasugrel hydrobromide, preparation and application thereof |
CN102050819A (zh) * | 2009-11-10 | 2011-05-11 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
CN102464658A (zh) * | 2010-11-03 | 2012-05-23 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
陈鑫,等: "Xa因子抑制剂的研究进展", 《中国药科大学学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103242307A (zh) * | 2013-05-17 | 2013-08-14 | 天津药物研究院 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
WO2014183666A1 (zh) * | 2013-05-17 | 2014-11-20 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
CN106478661A (zh) * | 2015-08-25 | 2017-03-08 | 华北制药集团新药研究开发有限责任公司 | 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103232446B (zh) | 2015-09-23 |
WO2014183666A1 (zh) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102464658B (zh) | 噁唑烷酮衍生物及其制备方法和用途 | |
CN103232446B (zh) | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 | |
CN115381827B (zh) | 苯骈三氮唑烷基衍生物在制备治疗或预防心血管疾病的药物中的应用 | |
CN103992276B (zh) | 4’-{[(2,4,5-三取代苯基)-1h-咪唑-1-基]甲基}联苯-2-甲酸衍生物 | |
CN103242307B (zh) | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 | |
JP2022503890A (ja) | 2-(1-アシルオキシ-n-ペンチル)安息香酸と塩基性アミノ酸またはアミノグアニジンによって形成される塩と、その製造方法及び用途 | |
Gürbüz et al. | Obesity is still a risk factor in coronary artery bypass surgery. | |
RU2716141C2 (ru) | Дейтерированные производные тиенопиперидина, способ их получения и применение | |
CN104163819A (zh) | 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途 | |
RU2739915C2 (ru) | Соединение, имеющее действие ингибирования агрегации тромбоцитов, и его соль, и содержащая такие соединения композиция для предупреждения или лечения тромботических заболеваний | |
CN102001971B (zh) | N-(4-胍基丁基)丁香酰胺衍生物及其医药用途 | |
Liechti et al. | Plasmodium falciparum cerebral malaria complicated by disseminated intravascular coagulation and symmetrical peripheral gangrene: case report and review | |
CN105748424A (zh) | 一种稳定的硫酸氢氯吡格雷阿司匹林双层片及其制备方法 | |
CN101023942A (zh) | 二氢杨梅素治疗心血管疾病的用途 | |
KR20070046099A (ko) | 항혈소판약 및 그의 제조방법 | |
TW200804283A (en) | Derivatives of 5, 8-quinolinedione exert antimicrobial activities | |
CN115364081B (zh) | 2,4-二羟基-6-甲氧基苯乙酮在制备调节凝血功能的药物中的用途 | |
JP2022530461A (ja) | アテローム性動脈硬化を治療するための医薬品の製造における化合物の使用 | |
CN104356093B (zh) | 含卤代苯基的反式环己烷酰胺类化合物和用途 | |
Raju et al. | Study of Association between Platelet Function and Anthropometry of Blood Donors in a Single Institution | |
CN105111119B (zh) | 一类卤代苯l‑薄荷醇类p2y12受体拮抗剂及其用途 | |
CN104513212B (zh) | 一类含硝基苯的恶二唑亚砜化合物、其制备方法和用途 | |
CN104356095B (zh) | 烷氧基苯基取代的反式环己烷酰胺类化合物和用途 | |
CN108606971A (zh) | 白及苷在制备止血药物方面的应用 | |
Mordi et al. | P20 A comparison of the cardiovascular effects of empagliflozin and liraglutide: a systematic review and meta-analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200921 Address after: 300171 No. eight, No. 109, Hedong Road, Hedong District, Tianjin Patentee after: Tianjin Drug Group Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. |
|
TR01 | Transfer of patent right |